| |APRIL 20264In 2026, the Indian pharmaceutical market is poised to grow by 7-9 percent, driven by strong domestic demand for chronic therapies and robust exports, with total revenue witnessing a significant upsurge as the country solidifies its position as a global supplier. The key drivers can be attributed towards demand in biosimilars, complex generics, and increased manufacturing of active pharmaceutical ingredients (APIs), coupled with the backing by government incentives.If we look at APIs And Intermediates domain, custom synthesis, Drug Intermediates, and Active Pharmaceutical Ingredients for various therapeutic substances have become some of the major driving factors today. Here's manufacturers must stay relevant by offering innovation-driven, optimal quality products and solutions.Furthermore, In 2026, India's nutraceutical R&D and manufacturing sector is booming, driven by a 20 percent CAGR, personalized nutrition, and a shift toward advanced delivery formats like effervescents and liquid capsules. Some of the key trends here include AI-driven R&D for immunity and cognitive health, strict adherence to clean-label standards, and increased production of herbal-based supplements.Additionally, the Indian oral care market is projected to reach USD 1.82 billion by 2034, growing at a 4.45 percent CAGR from 2026, driven by premiumization, natural ingredients, and e-commerce growth. At the same time, In 2026, India's pharmaceutical cleanroom and sterile manufacturing sectors are characterized by a shift toward modular infrastructure, digitalization (Industry 4.0), and capacity expansion driven by Production-Linked Incentive (PLI) schemesThe diagnostic consumables and kits sector in India in 2026 is experiencing high-volume growth, projected at a 6.49% CAGR to reach USD 1.94 billion by the end of 2026, driven by chronic disease prevalence, infrastructure expansion, and a push toward local manufacturing. Key trends highlight a shift toward high-precision reagents, point-of-care (POC) testing, and sustainable, automation-compatible products.However, irrespective of industry verticals, it is imperative that manufacturers and service providers must ensure optimal quality, regulatory and service deliverability standards to stay relevant in India's fiercely competitive market.Understanding how the players in their respective fields have been aiding India's burgeoning pharmaceutical landscape to rank among the best at the global front, India Pharma Outlook brings to you our `APRIL VOL. II Edition - 2026.' This meticulously crafted issue will shed light on the manufacturing, R&D and service deliverability of these selected players and walk our reader through their promising journey. We will showcase why these players have been'.Shiwani Pradhan Assistant Editoreditor@indiapharmaoutlook.comCreating Pharma Center of Excellence in 2026 & BeyondVol 5 · Issue 04 - 04 · APRIL , 2026Publisher Alok ChaturvediManaging EditorSamrat Pradhan Assistant EditorShiwani Pradhan Editorial TeamViswanathan AThiruamuthan T K GM - Media & Graphic Designing VisualizerPrabhu DuttaDesignerRutika MohantyMonalisha Malik Advertising QueriesRahul KumarGM Sales & MarketingRavi kalgisales@indiapharmaoutlook.com Editorial Querieseditor@indiapharmaoutlook.comCirculation Manager Magendran PerumalMagazine Price is Rs. 150 per issuePrinted and Published By Alok Chaturvedi on behalf of Info Connect Web Technologies India Pvt. Ltd. and Printed at Precision Fototype Services at Sri Sabari Shopping Complex, 24 Residency Road Bangalore-560025 and Published At No. 124, 2nd Floor, Surya Chambers, Old Airport Road, Murugeshpalya, Bangalore-560017.Publisher Alok ChaturvediCopyright © 2026 Info Connect Web Technologies India Pvt. Ltd., All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher.
< Page 3 | Page 5 >